Enhanced synthesis of epoxyeicosatrienoic acids by cholesterol-fed rabbit aorta

Am J Physiol. 1991 Sep;261(3 Pt 2):H843-52. doi: 10.1152/ajpheart.1991.261.3.H843.

Abstract

Arachidonic acid metabolism via cyclooxygenase, lipoxygenase, and cytochrome P-450 epoxygenase was investigated in thoracic aortic tissue obtained from rabbits fed either standard rabbit chow or chow containing 2% cholesterol. Aortic strips were incubated with [14C]arachidonic acid and A23187. Metabolites from extracted media were resolved by high-pressure liquid chromatography (HPLC). Normal and cholesterol-fed rabbit aortas synthesized prostaglandins (PGs) and hydroxyeicosatetraenoic acids (HETEs). The major cyclooxygenase products were 6-keto-PGF1 alpha and PGE2. Basal aortic 6-keto-PGF1 alpha production was slightly reduced in cholesterol-fed compared with normal rabbits. 12(S)- and 15(S)-HETE were the major aortic lipoxygenase products from both normal and cholesterol-fed rabbits. The structures were confirmed by gas chromatography-mass spectrometry (GC-MS). Only cholesterol-fed rabbit aortas metabolized arachidonic acid via cytochrome P-450 epoxygenase to the epoxyeicosatrienoic acids (EETs). 14,15-, 11,12-, 8,9-, and 5,6-EET were identified based on comigration on HPLC with known 14C-labeled standards and typical mass spectra. Incubation of normal aorta with 14,15-EET decreased the basal synthesis of 6-keto-PGF1 alpha. The other EETs were without effect. The four EET regioisomers relaxed the norepinephrine-precontracted normal and cholesterol-fed rabbit aorta. The relaxation response to 14,15-EET was greater in aortas from cholesterol-fed rabbits. These studies demonstrate that hypercholesterolemia, before the development of atherosclerosis, alters arachidonic acid metabolism via both the cyclooxygenase and epoxygenase pathways.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
  • 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine / pharmacology
  • 6-Ketoprostaglandin F1 alpha / metabolism
  • 8,11,14-Eicosatrienoic Acid / analogs & derivatives*
  • 8,11,14-Eicosatrienoic Acid / metabolism
  • Animals
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism*
  • Arachidonic Acids / metabolism*
  • Carbon Radioisotopes
  • Cholesterol, Dietary / pharmacology*
  • Clotrimazole / pharmacology
  • Diet, Atherogenic*
  • Hydroxyeicosatetraenoic Acids / isolation & purification
  • Hydroxyeicosatetraenoic Acids / metabolism*
  • In Vitro Techniques
  • Indomethacin / pharmacology
  • Kinetics
  • Masoprocol / pharmacology
  • Metyrapone / pharmacology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism
  • Rabbits
  • Reference Values
  • Stereoisomerism

Substances

  • Arachidonic Acids
  • Carbon Radioisotopes
  • Cholesterol, Dietary
  • Hydroxyeicosatetraenoic Acids
  • 6-Ketoprostaglandin F1 alpha
  • 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid
  • 11,12-epoxy-5,8,14-eicosatrienoic acid
  • 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine
  • 11-hydroxy-5,8,12,14-eicosatetraenoic acid
  • 15-hydroxy-5,8,11,13-eicosatetraenoic acid
  • Masoprocol
  • 5,6-epoxy-8,11,14-eicosatrienoic acid
  • 8,9-epoxyeicosatrienoic acid
  • 14,15-epoxy-5,8,11-eicosatrienoic acid
  • 8,11,14-Eicosatrienoic Acid
  • Clotrimazole
  • Indomethacin
  • Metyrapone